PCAT1 and prostate neoplasm: MEG3, as lncRNA, specifically targets genes involving the TGF-β pathway by binding to the distal regulatory region of the promoter and possesses the property of activating p53 transcription.[43,44] Several studies have pointed out the potential of lncRNAs as biomarkers for cancer diagnosis, such as the high expression of PCAT-1, PRNCR1, PCGEM, PlncRNA1, and PCAT-18 in prostate tumors.[45] Although there have been studies demonstrating the correlation between lncRNA differential expression and UM progression, the precise intracellular mechanisms remain to be elucidated.[46,47]